01:01 PM EDT, 08/21/2025 (MT Newswires) -- BriaCell Therapeutics ( BCTX ) said Thursday that its board has approved a share consolidation on the basis of one new share for every 10 currently outstanding shares to ensure continued compliance with the listing requirements of The Nasdaq Capital Market.

The consolidation is subject to approval by the Nasdaq and the Toronto Stock Exchange, and is expected to become effective on Aug. 25, the company said.

Price: 0.66, Change: -0.03, Percent Change: -4.48